Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
A test in context: lipoprotein (a) diagnosis, prognosis, controversies, and emerging therapies
S Tsimikas - Journal of the American College of Cardiology, 2017 - jacc.org
Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …
Calcific aortic stenosis
Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …
NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis
S Tsimikas, S Fazio, KC Ferdinand… - Journal of the American …, 2018 - jacc.org
Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease
continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling …
continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling …
Lipoprotein (a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis
Abstract Background: Lipoprotein (a)[Lp (a)], a major carrier of oxidized phospholipids
(OxPL), is associated with an increased incidence of aortic stenosis (AS). However, it …
(OxPL), is associated with an increased incidence of aortic stenosis (AS). However, it …
Calcific aortic valve disease: mechanisms, prevention and treatment
Calcific aortic valve disease (CAVD) is the most common disorder affecting heart valves and
is characterized by thickening, fibrosis and mineralization of the aortic valve leaflets …
is characterized by thickening, fibrosis and mineralization of the aortic valve leaflets …
Elevated lipoprotein (a) and risk of atrial fibrillation: an observational and mendelian randomization study
Background Atrial fibrillation (AF) is a cardiac arrhythmia associated with an elevated risk of
stroke, heart failure, and mortality. However, preventative therapies are needed with …
stroke, heart failure, and mortality. However, preventative therapies are needed with …
Oxidized phospholipids as a unifying theory for lipoprotein (a) and cardiovascular disease
MB Boffa, ML Koschinsky - Nature Reviews Cardiology, 2019 - nature.com
Epidemiological and clinical studies over the past decade have firmly established that
elevated plasma concentrations of lipoprotein (a)(Lp (a)) are an important, independent and …
elevated plasma concentrations of lipoprotein (a)(Lp (a)) are an important, independent and …
Spatiotemporal multi-omics map** generates a molecular atlas of the aortic valve and reveals networks driving disease
Background: No pharmacological therapy exists for calcific aortic valve disease (CAVD),
which confers a dismal prognosis without invasive valve replacement. The search for …
which confers a dismal prognosis without invasive valve replacement. The search for …